Phase II Trial of Amsacrine Plus Intermediate-dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia - Concepedia

Concepedia

Publication | Open Access

Phase II Trial of Amsacrine Plus Intermediate-dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia

DOI Full Paper Access

21

Citations

20

References

2005

Year

Woo Jin Sung, Dong Hwan Kim, Sang Kyun Sohn, Jong Gwang Kim, Jin Ho Baek, Seok Bong Jeon, Joon Ho Moon, Byung Min Ahn, Kyu Bo Lee

Japanese Journal of Clinical Oncology

Abstract

A salvage therapy consisting of amsacrine plus IDAC with or without etoposide appears to be safe and an effective bridge therapy into a stem cell transplantation programme for patients with refractory or relapsed acute leukemia.

References

	Year	Citations
Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults Rose Ruth Ellison, James F. Holland, Marise Weil, Blood	1968	548
Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10) Ian Hann, Richard Stevens, Anthony H. Goldstone, Blood	1997	301
High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. R H Herzig, Hillard M. Lazarus, Steven N. Wolff, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaPathologyPharmacotherapyImmunotherapyMyeloid Neoplasia	1985	182
The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series B. F. CAIN, Graham J. Atwell European Journal of Cancer (1965) HeterocyclicExperimental Antitumour PropertiesOrganic ChemistryChemistryPharmacology	1974	158
Failure of remission induction in acute myelocytic leukemia Harvey D. Preisler Medical and Pediatric Oncology Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaImmunologyHematology	1978	143
High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. John Hines, Martin M. Oken, J. J. Mazza, Journal of Clinical Oncology Hematological MalignancyOncologyRemission PatientsMedicineAplastic Anemia	1984	119
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine Kenneth F. Bradstock Blood	2004	100
4′-(9-Acridinylamino) Methanesulfon-<i>m</i>-Anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute Leukemia Sewa S. Legha Annals of Internal Medicine	1980	91
Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. Zalmen A. Arlin, Robert B. Sklaroff, Toby Gee, PubMed Ii TrialHematological MalignancyMedicinal ChemistryOncologyMedicine	1980	81
Treatment of refractory AML. Elihu H. Estey PubMed	1996	69

Page 1